The Modulation of Arachidonic Acid Metabolism and Blood Pressure-Lowering Effect of Honokiol in Spontaneously Hypertensive Rats.
arachidonic acid
epoxide hydrolase
honokiol
hypertension
natural products
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
25 May 2022
25 May 2022
Historique:
received:
05
04
2022
revised:
23
05
2022
accepted:
24
05
2022
entrez:
10
6
2022
pubmed:
11
6
2022
medline:
14
6
2022
Statut:
epublish
Résumé
Cardiovascular diseases have consistently been the leading cause of death in the United States over the last two decades, with 30% of the adult American population having hypertension. The metabolites of arachidonic acid (AA) in the kidney play an important role in blood pressure regulation. The present study investigates the antihypertensive effect of honokiol (HON), a naturally occurring polyphenol, and examines its correlation to the modulation of AA metabolism. Spontaneously hypertensive rats (SHR) were randomly divided into four groups. Treatment groups were administered HON intraperitoneally at concentrations of 5, 20, and 50 mg/kg. Blood pressure was monitored at seven-day intervals. After a total of 3 weeks of treatment, the rats were euthanized and the kidney tissues were collected to examine the activity of the two major enzymes involved in AA metabolism in the kidney, namely cytochrome P450 (CYP)4A and soluble epoxide hydrolase (sEH). Rats treated with HON did not experience the rise in blood pressure observed in the untreated SHR. High-dose HON significantly reduced blood pressure and inhibited the activity and protein expression of the CYP4A enzyme in the rat kidney. The activity of the sEH enzyme in renal cytosol was significantly inhibited by medium and high doses of HON. Our data demonstrate the antihypertensive effect of HON and provide a novel mechanism for its underlying cardioprotective properties.
Sections du résumé
BACKGROUND
BACKGROUND
Cardiovascular diseases have consistently been the leading cause of death in the United States over the last two decades, with 30% of the adult American population having hypertension. The metabolites of arachidonic acid (AA) in the kidney play an important role in blood pressure regulation. The present study investigates the antihypertensive effect of honokiol (HON), a naturally occurring polyphenol, and examines its correlation to the modulation of AA metabolism.
METHODS
METHODS
Spontaneously hypertensive rats (SHR) were randomly divided into four groups. Treatment groups were administered HON intraperitoneally at concentrations of 5, 20, and 50 mg/kg. Blood pressure was monitored at seven-day intervals. After a total of 3 weeks of treatment, the rats were euthanized and the kidney tissues were collected to examine the activity of the two major enzymes involved in AA metabolism in the kidney, namely cytochrome P450 (CYP)4A and soluble epoxide hydrolase (sEH).
RESULTS
RESULTS
Rats treated with HON did not experience the rise in blood pressure observed in the untreated SHR. High-dose HON significantly reduced blood pressure and inhibited the activity and protein expression of the CYP4A enzyme in the rat kidney. The activity of the sEH enzyme in renal cytosol was significantly inhibited by medium and high doses of HON.
CONCLUSION
CONCLUSIONS
Our data demonstrate the antihypertensive effect of HON and provide a novel mechanism for its underlying cardioprotective properties.
Identifiants
pubmed: 35684335
pii: molecules27113396
doi: 10.3390/molecules27113396
pmc: PMC9182499
pii:
doi:
Substances chimiques
Antihypertensive Agents
0
Biphenyl Compounds
0
Lignans
0
honokiol
11513CCO0N
Arachidonic Acid
27YG812J1I
Cytochrome P-450 CYP4A
EC 1.14.15.3
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
N Engl J Med. 2000 Jan 20;342(3):154-60
pubmed: 10639540
J Chem Neuroanat. 2022 Mar;120:102061
pubmed: 34952137
Int J Mol Sci. 2020 Sep 08;21(18):
pubmed: 32911626
Am J Prev Med. 2017 Dec;53(6 Suppl 2):S115-S117
pubmed: 29153111
Pharmacol Ther. 2017 Dec;180:62-76
pubmed: 28642117
Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):761-770
pubmed: 31065969
Circulation. 2019 Mar 5;139(10):e56-e528
pubmed: 30700139
Planta Med. 2018 Nov;84(16):1151-1164
pubmed: 29925102
ISRN Pharmacol. 2014 Mar 09;2014:683508
pubmed: 24734194
Lancet. 1999 Aug 7;354(9177):447-55
pubmed: 10465168
J Am Soc Nephrol. 2017 Oct;28(10):2845-2855
pubmed: 28701518
J Hypertens. 2009 Oct;27(10):1948-54
pubmed: 19587609
Curr Drug Metab. 2004 Jun;5(3):245-56
pubmed: 15180494
Am J Hypertens. 2000 May;13(5 Pt 1):564-7
pubmed: 10826412
Turk Neurosurg. 2021;31(6):936-943
pubmed: 34664691
J Biol Chem. 1951 Nov;193(1):265-75
pubmed: 14907713
Biol Pharm Bull. 2010;33(3):427-31
pubmed: 20190404
Phytomedicine. 2021 Sep;90:153647
pubmed: 34362632
J Biol Chem. 2000 Feb 11;275(6):4118-26
pubmed: 10660572
Front Pharmacol. 2022 Jan 17;12:798642
pubmed: 35111064
Sheng Li Xue Bao. 2018 Dec 25;70(6):591-599
pubmed: 30560267
Hypertension. 2013 Jun;61(6):1360-83
pubmed: 23608661
J Clin Hypertens (Greenwich). 2018 Feb;20(2):273-279
pubmed: 29316211
J Assoc Physicians India. 2022 Dec;69(12):11-12
pubmed: 35057591
J Cardiovasc Pharmacol. 2021 Nov 1;78(5):e738-e742
pubmed: 34321400
Am J Hypertens. 2022 Jul 1;35(7):573-586
pubmed: 35404993
Expert Opin Ther Pat. 2022 Jun;32(6):629-647
pubmed: 35410559